Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians with Nonvalvular Atrial Fibrillation

Stroke

Volumn 47, Issue 2, 2016, Pages 441-449

  Chan, Yi Hsin ^a,b   Yen, Kun Chi ^a,b   See, Lai Chu ^b,c   Chang, Shang Hung ^a,b   Wu, Lung Sheng ^a,b   Lee, Hsin Fu ^a,b   Tu, Hui Tzu ^b   Yeh, Yung Hsin ^a,b   Kuo, Chi Tai ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Anticoagulant agents; Atrial fibrillation; Direct thrombin inhibitors; Hemorrhage; Mortality; Warfarin

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ASIAN; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHADS2 SCORE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONVALVULAR ATRIAL FIBRILLATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPLICATION; FACTUAL DATABASE; HEMORRHAGE; HOSPITALIZATION; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; STROKE; TAIWAN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DABIGATRAN; DATABASES, FACTUAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HOSPITALIZATION; HUMANS; INTRACRANIAL HEMORRHAGES; LOGISTIC MODELS; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; TAIWAN; WARFARIN;

EID: 84953301952     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.011476     Document Type: Article

References (43)

1. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213-220. doi: 10.2147/CLEP.S47385.
2. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27:1760-1764.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
4. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006;118:321-333. doi: 10.1016/j.thromres.2005.08.007.
5. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50:309-315. doi: 10.1016/j. jacc.2007.01.098.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561.
7. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175:18-24. doi: 10.1001/jamainternmed.2014.5398.
8. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157-164. doi: 10.1161/CIRCULATIONAHA.114.012061.
9. Sipahi I, Celik S, Tozun N. A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. JAMA Intern Med. 2014;174:150-151. doi: 10.1001/jamainternmed.2013.12217.
10. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callreús T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61:2264-2273. doi: 10.1016/j. jacc.2013.03.020.
11. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272-1274. doi: 10.1056/NEJMp1302834.
12. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al; RELY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013;44:1891-1896. doi: 10.1161/STROKEAHA.113.000990.
13. Background. National Health Insurance Research Database Web site. http://nhird.nhri.org.tw/en/index.html. Accessed November 12, 2015.
14. Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke. 2002;33:2465-2470.
15. Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf. 2008;17:20-26. doi: 10.1002/pds.1518.
16. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke. 2005;36:1776-1781. doi: 10.1161/01.STR.0000174293.17959.a1.
17. Austin PC. The use of propensity score methods with survival or timeto-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242-1258. doi: 10.1002/sim.5984.
18. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
19. Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol. 2015;180:246-254. doi: 10.1016/j.ijcard.2014.11.182.
20. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, et al; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and-experienced cohorts with atrial fibrillation. Circulation. 2010;122:2246-2253. doi: 10.1161/CIRCULATIONAHA.110.973735.
21. Sorensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, et al. Dabigatran use in danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013;3:e002758.
22. Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr. 2004;79:31-39.
23. Breuer L, Ringwald J, Schwab S, Köhrmann M. Ischemic stroke in an obese patient receiving dabigatran. N Engl J Med. 2013;368:2440-2442. doi: 10.1056/NEJMc1215900.
24. Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol. 2011;155:137-149. doi: 10.1111/j.1365-2141.2011.08826.x.
25. Body Mass Index (BMI) by Country. ChartsBin Web site. http://chartsbin. com/view/577. Accessed November 6, 2015.
26. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005;104:157-163.
27. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:236-242. doi: 10.1002/pds.2087.
28. Chen SJ, Liu CJ, Chao TF, Wang KL, Chen TJ, Chou P, et al. Dental scaling and atrial fibrillation: a nationwide cohort study. Int J Cardiol. 2013;168:2300-2303. doi: 10.1016/j.ijcard.2013.01.192.
29. Lin LJ, Cheng MH, Lee CH, Wung DC, Cheng CL, Kao Yang YH. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-a nationwide descriptive study in Taiwan. Clin Ther. 2008;30:1726-1736. doi: 10.1016/j.clinthera.2008.09.010.
30. Chang CH, Lee YC, Tsai CT, Chang SN, Chung YH, Lin MS, et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis. 2014;232:224-230. doi: 10.1016/j.atherosclerosis.2013.11.036.
31. Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc. 2015;114:254-259. doi: 10.1016/j.jfma.2013.09.009.
32. Chang CH, Lin CH, Caffrey JL, Lee YC, Liu YC, Lin JW, et al. Risk of Intracranial Hemorrhage From Statin Use in Asians: A Nationwide Cohort Study. Circulation. 2015;131:2070-2078. doi: 10.1161/CIRCULATIONAHA.114.013046.
33. Peng YL, Hu HY, Luo JC, Hou MC, Lin HC, Lee FY. Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study. Osteoporos Int. 2014;25:1617-1623. doi: 10.1007/s00198-014-2647-z.
34. Lin CC, Hu HY, Luo JC, Peng YL, Hou MC, Lin HC, et al. Risk factors of gastrointestinal bleeding in clopidogrel users: a nationwide population-based study. Aliment Pharmacol Ther. 2013;38:1119-1128. doi: 10.1111/apt.12483.
35. Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am J Kidney Dis. 2007;49:46-55. doi: 10.1053/j.ajkd.2006.10.007.
36. Chang CH, Chang YC, Lee YC, Liu YC, Chuang LM, Lin JW. Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study. J Gastroenterol Hepatol. 2015;30:155-162. doi: 10.1111/jgh.12657.
37. Chao TF, Wang KL, Liu CJ, Lin YJ, Chang SL, Lo LW, et al. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. J Am Coll Cardiol. 2015;66:1339-1347. doi: 10.1016/j.jacc.2015.07.026.
38. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635-642. doi: 10.1016/j.jacc.2014.11.046.
39. Chao TF, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, et al. Ratecontrol treatment and mortality in atrial fibrillation. Circulation. 2015;132:1604-1612.
40. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. J Am Coll Cardiol. 2014;64:1658-1665. doi: 10.1016/j.jacc.2014.06.1203.
41. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al; ROCKET AF Investigators. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2:e000067. doi: 10.1161/JAHA.112.000067.
42. Chen PC, Lip GY, Yeh G, Lin HJ, Chien KL. Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study. PLoS One. 2015;10:e0125257. doi: 10.1371/journal.pone.0125257.
43. Rolden HJA, Grutters JPC, Jan van derWilt G, Maas A.H.E.M. Closing the information gap between clinical and postmarketing trials: The case of dabigatran. Eur Heart J Cardiovasc Pharmacotherapy. 2015;1:153-156.